XJPX
7575
Market cap594mUSD
Jul 10, Last price
1,363.00JPY
1D
-0.87%
1Q
-5.28%
Jan 2017
16.95%
Name
Japan Lifeline Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Japan Lifeline Co., Ltd. is a medical technology firm based in Japan that specializes in cardiovascular healthcare devices. Its operations encompass research, manufacturing, global procurement, and sales of these specialized medical instruments within the country. The company's diverse product range includes solutions for cardiac rhythm management, such as pacemakers, implantable cardioverter defibrillators (including subcutaneous models), cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support tools. For electrophysiology and ablation procedures, Japan Lifeline offers various electrophysiological and ablation catheters (like irrigated tip versions), endoscopic balloon ablation systems, esophageal temperature monitors, internal atrial cardioversion systems, and radio-frequency transseptal needles. Furthermore, its portfolio extends to cardiovascular and endografting products, including vascular, open, and abdominal stent-grafts. In the transvascular intervention segment, the company provides PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and devices for closing atrial septal defects. Complementing these, its gastrointestinal intervention solutions encompass radiofrequency ablation systems, self-expandable colonic stents, and endoscopic guidewires. Established in 1981, Japan Lifeline Co., Ltd. maintains its headquarters in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||